Core Insights - Stereotaxis reported third-quarter financial results for 2025, highlighting a focus on commercial progress and regulatory advancements in surgical robotics for minimally invasive endovascular interventions [1][2]. Financial Performance - Total revenue for Q3 2025 was $7.5 million, with system revenue at $1.9 million and recurring revenue at $5.6 million, compared to $4.4 million and $4.8 million in the same quarter of the previous year [3]. - Gross margin for the quarter was 55%, with recurring revenue gross margin at 67% and system gross margin at 19%, affected by fixed overhead costs [4]. - Operating expenses were $10.7 million, including $4.1 million in non-cash charges, with adjusted operating expenses decreasing to $6.6 million from $7.2 million year-over-year [5]. - The operating loss was ($6.6) million, and the net loss was ($6.5) million, compared to ($6.3) million and ($6.2) million in the previous year [6]. Cash Position and Liquidity - As of September 30, 2025, Stereotaxis had cash and cash equivalents of $10.5 million and no debt, with an expected increase to $14.5 million following an upcoming financing closing [7]. Future Outlook - The company anticipates Q4 2025 revenue to exceed $9 million, with system revenue around $3 million and recurring revenue greater than $6 million, supporting over 20% annual revenue growth for 2025 [8]. - Sustained growth in both system and recurring revenue is expected in 2026, with quarterly revenue projected to surpass an average of $10 million [8][9].

Core Insights - Stereotaxis has successfully completed the world's first procedures using MAGiC Sweep™, a robotically-navigated high-density electrophysiology mapping catheter, marking a significant advancement in surgical robotics for minimally invasive endovascular interventions [1][2]. Company Overview - Stereotaxis is a pioneer and global leader in innovative surgical robotics, focusing on minimally invasive endovascular interventions. The company aims to enhance patient care through robotic precision and safety, while also expanding access to such therapies [3]. - The technology developed by Stereotaxis has been utilized to treat over 150,000 patients globally, including regions such as the United States, Europe, and Asia [3]. Product Launch and Regulatory Status - Following FDA clearance, Stereotaxis has initiated the commercial launch of MAGiC Sweep in the United States, with plans for regulatory clearance in Europe [2].